We retrieved information on progression of COVID-19 vaccination and newly diagnosed cases of SARS-CoV-2 infection from the weekly report of the Italian National Institute of Health (Istituto Superiore di Sanità, ISS; Last available update, January 1, 2022). The rate of SARS-CoV-2 infections in non-vaccinated, vaccinated with primary cycle <120 days and in those who received a recent booster vaccine dose was 2.5%, 0.7% and 0.4%, respectively. Overall, the risk of SARS-CoV-2 infection was 71% (OR, 0.29; 95%CI, 0.29-0.29; p<0.001) and 86% (OR, 0.14; 95%CI, 0.14-0.14; p<0.001) lower in people who received primary vaccination <120 days and recent booster dose compared to the unvaccinated population, but was also nearly half (OR, 0.49; 95%CI, 0.48-0.49; p<0.001) in those who received a recent booster dose compared to the population who only recently completed the primary vaccination cycle.
COVID-19 vaccination is highly effective to prevent SARS-CoV-2 circulation
Mattiuzzi, Camilla;Lippi, Giuseppe
2022-01-01
Abstract
We retrieved information on progression of COVID-19 vaccination and newly diagnosed cases of SARS-CoV-2 infection from the weekly report of the Italian National Institute of Health (Istituto Superiore di Sanità, ISS; Last available update, January 1, 2022). The rate of SARS-CoV-2 infections in non-vaccinated, vaccinated with primary cycle <120 days and in those who received a recent booster vaccine dose was 2.5%, 0.7% and 0.4%, respectively. Overall, the risk of SARS-CoV-2 infection was 71% (OR, 0.29; 95%CI, 0.29-0.29; p<0.001) and 86% (OR, 0.14; 95%CI, 0.14-0.14; p<0.001) lower in people who received primary vaccination <120 days and recent booster dose compared to the unvaccinated population, but was also nearly half (OR, 0.49; 95%CI, 0.48-0.49; p<0.001) in those who received a recent booster dose compared to the population who only recently completed the primary vaccination cycle.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
